What Is Teriparatide? Dosage, Half-Life & How to Track It

What teriparatide is and how it works

Teriparatide is a recombinant version of the first 34 amino acids of human parathyroid hormone (PTH) — the same hormone your body uses to regulate blood calcium. The counterintuitive part is that continuous PTH exposure, as in a parathyroid tumor, breaks bone down, while a sharp daily pulse that clears within a few hours flips the effect to net bone building. That timing distinction is the entire reason the dosing schedule is a strict once-daily injection — splitting the dose or giving it continuously would reverse the benefit.

This makes teriparatide an anabolic agent, a genuinely different drug class from bisphosphonates (alendronate, zoledronic acid) or denosumab, which only slow the resorption side of bone turnover. A bone-formation marker (P1NP) typically doubles within the first 1–3 months of starting, which is the biochemical signature of that anabolic pulse doing its job.

Because of that mechanism, teriparatide is generally reserved for very-high-risk osteoporosis — postmenopausal women or men who have already fractured or failed first-line bisphosphonate therapy — rather than used as a first choice, and it always sits at the front of a longer treatment sequence, not the end of one.

Dosing & the 28-day pen

Teriparatide ships as a pre-filled, pre-mixed pen — there is no bacteriostatic-water reconstitution step. Each pen delivers a fixed 20 mcg dose per injection from a 250 mcg/mL solution, injected once daily into the thigh or abdomen with sites rotated.

The pen ships ready to use at a fixed concentration, so there is no vial-and-water math to run the way there is for a lyophilized peptide — the number worth tracking instead is which day of the pen, and of the 24-month lifetime cap, you are on. Pens must be discarded 28 days after first use regardless of remaining volume, and stored refrigerated without freezing.

Half-life & why the schedule is strict

Teriparatide’s subcutaneous half-life is roughly 1 hour, with a peak blood level around 30 minutes post-injection — a short, sharp pulse by design. That pulse-then-clear pattern is what triggers bone formation rather than resorption; a longer-acting version would behave more like the constant PTH exposure that breaks bone down instead.

The other hard time limit is the 24-month lifetime cap, which is not a per-course restriction — once used, that allowance does not reset. This originated from high-dose rat carcinogenicity data; large human postmarketing studies found no elevated osteosarcoma risk at the approved dose, and the FDA removed the drug’s black-box warning in 2020, but the 24-month cap itself was not lifted.

What to track & the mandatory follow-up therapy

Common early side effects are dose-related and mostly front-loaded into the first weeks: nausea and transient dizziness or lightheadedness within a few hours of injection, often improved by dosing at bedtime and sitting or lying down after the first several doses. Teriparatide also transiently raises blood calcium after each injection, which is why periodic serum calcium monitoring is standard.

The single most important thing to track is not a side effect — it is the calendar. Bone density gains from teriparatide reverse without follow-up treatment: a bisphosphonate or denosumab needs to start within about 4–8 weeks of the last dose to lock in the gains. Missing that window is a far more consequential mistake than missing an individual daily dose.

Frequently asked questions